CIK 0000715446
- Non-accelerated filer
- Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 112622630
- Phone
- +1 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Vice President-Finance & CFO sold 500 shares at $3.76 ($1,880)
- 4 Open-market sale Vice President-Finance & CFO sold 3,500 shares at an average $3.78 ($13,234)
- 4 Open-market buy Director bought 5,616 shares at $4.59 ($25,777)
- 4 Open-market buy Director bought 1,000 shares at $4.70 ($4,700)
- 4 Open-market buy Director bought 1,400 shares at $4.49 ($6,286)
- 4 Open-market buy Director bought 700 shares at an average $4.91 ($3,437)
- 4 Open-market buy Director bought 100 shares at $5.15 ($515)
- 4 Open-market buy Director bought 681 shares at an average $5.28 ($3,598)
- 4 Open-market buy Director bought 600 shares at $5.62 ($3,372)
- 4 Open-market buy Director bought 500 shares at $4.90 ($2,450)
- 4 Open-market buy Director bought 300 shares at an average $5.29 ($1,588)
- 4 Open-market buy Director bought 600 shares at an average $4.46 ($2,673)
- 4 Open-market buy Director bought 2,000 shares at $3.95 ($7,900)
- 4 Open-market buy Director bought 2,000 shares at $4.15 ($8,300)
- 4 Open-market buy Director bought 300 shares at $4.66 ($1,398)
- 4 Open-market buy Director bought 1,700 shares at $4.49 ($7,633)
- 4 Open-market buy Director bought 1,500 shares at $5.23 ($7,845)
- 4 Open-market buy Director bought 3,050 shares at an average $5.15 ($15,704)
Page 13 of 24 · 471 filings